Despite headlines about rapid-growth companies, the typical startup journey is slowing dramatically. The median time between Series A and B rounds is now close to 1,000 days (almost 3 years), creating a barbell market where a few companies raise quickly while the majority face a much longer path to their next milestone.
Related Insights
The 2020-2021 biotech "bubble" pushed very early-stage companies into public markets prematurely. The subsequent correction, though painful, has been a healthy reset. It has forced the sector back toward a more suitable, long-duration private funding model where companies can mature before facing public market pressures.
eSentire took seven years to hit its first million in revenue, a slow "death march." However, it only took three years to get from $1M to $10M. This highlights that the real test of scalability isn't initial traction but the speed of the next 10x growth phase.
Raise capital when you can clearly see upcoming growth and need resources to service it. Tying your timeline to operational milestones, like onboarding new customers, creates genuine urgency and momentum. This drives investor FOMO and helps close deals more effectively than an arbitrary deadline.
The current fundraising environment is the most binary in recent memory. Startups with the "right" narrative—AI-native, elite incubator pedigree, explosive growth—get funded easily. Companies with solid but non-hype metrics, like classic SaaS growers, are finding it nearly impossible to raise capital. The middle market has vanished.
Despite seeing 100x revenue multiples reminiscent of 2021, VCs are not accelerating their fund deployment or rushing back to fundraise. This more measured pace indicates a potential lesson learned from the last bubble, where rapid deployment led to poor vintage performance and pressure from LPs.
Investors like Stacy Brown-Philpot and Aileen Lee now expect founders to demonstrate a clear, rapid path to massive scale early on. The old assumption that the next funding round would solve for scalability is gone; proof is required upfront.
Data shows companies with the highest seed valuations graduate to Series A only slightly more often than those in the 2nd and 3rd quartiles. The real danger lies at the bottom: companies with the lowest-quartile valuations are only half as likely to raise a Series A, suggesting raising too little capital is a critical failure point.
Aggregate venture capital investment figures are misleading. The market is becoming bimodal: a handful of elite AI companies absorb a disproportionate share of capital, while the vast majority of other startups, including 900+ unicorns, face a tougher fundraising and exit environment.
